What is it?
Prescription wakefulness drug, not a supplement
1Armodafinil is the R form of modafinil and is sold as a prescription wakefulness promoting medication. It belongs in synthetic wakefulness/research-compound context, not in accessory or ordinary supplement categories.
Names, aliases and forms
Potential effects and evidence map
Armodafinil has human evidence for excessive sleepiness in label-specified clinical contexts, especially shift work disorder, narcolepsy, and residual sleepiness in obstructive sleep apnea during airway therapy. That evidence should not be generalized into an unsupervised healthy-user productivity or studying protocol. The safety and legal context is dominated by prescription labeling, long exposure, serious rash or hypersensitivity, psychiatric and cardiovascular warnings, contraception or drug interactions, and controlled-substance status.
Armodafinil improves wakefulness in label-specified excessive-sleepiness contexts under prescription labeling, not as a general wellness supplement.
Attention benefits are secondary to wakefulness management and should not be reframed as healthy-user study enhancement.
There is no strong basis to sell armodafinil as a memory or learning supplement.
Typical dosages and timing
For narcolepsy or obstructive sleep apnea, the U.S. label gives 150-250 mg once daily in the morning. For shift work disorder, it gives 150 mg about one hour before the work shift. This is prescription-label context, not a self-directed nootropic dose.
Timing & effect horizon
Armodafinil has long wake-promoting exposure, with pharmacokinetic work showing a long The time for blood levels to fall by half during the final elimination phase.Source similar to modafinil but a different blood-level profile. Late or repeated use can plausibly affect sleep timing.
Safety, side effects and risk profile
Insomnia, headache, anxiety/nervousness, and long wake-promoting exposure are expected practical risks, especially with late timing or sleep deprivation.
Labeling highlights CYP interactions, reduced effectiveness of steroidal contraceptives, and medication-review needs with drugs such as cyclosporine, omeprazole, diazepam, phenytoin, and propranolol.
In the United States, armodafinil is a prescription controlled substance medication; sport and workplace rules may add separate restrictions.
Blood pressure, heart disease, arrhythmia history, stimulant stacking, and psychiatric activation need clinician review before use.
Pregnancy, breastfeeding, and hormonal-contraception reliability require explicit medical review; online/off label use is not appropriate for these contexts.
Headache, nausea, dizziness, and anxiety-type adverse effects are common enough to matter in product comparison.
DailyMed labeling warns about serious rash and hypersensitivity reactions, psychiatric symptoms, blood pressure/cardiovascular review, and the need to stop and seek medical care for concerning reactions. These warnings should be visible in any buyer facing comparison.
Interactions and cautions
Armodafinil can reduce steroidal-contraceptive effectiveness during use and for one month after discontinuation; use alternative or concomitant contraception as the label directs. It has CYP3A4/5-induction and CYP2C19-inhibition considerations. Medication review matters particularly for CYP-affected medicines, warfarin, and MAOIs.
Legal and regulatory status
In the United States, the DailyMed label describes armodafinil as a prescription Schedule IV controlled substance. This does not determine international scheduling, import rules, online-pharmacy legality, workplace policy, or sport rules.
WADA's 2026 Prohibited List places modafinil in S6.A non-specified stimulants, prohibited in competition, and includes relevant optical isomers. Armodafinil is R-modafinil; athletes in WADA-governed sport should regard it as prohibited in competition and confirm any sport-specific process with their governing body.
Practical buying and quality notes
- Compare armodafinil listings by prescription legitimacy, dose strength, source quality, expiration, country rules, and pharmacist/clinician oversight. Do not regard anonymous tablets or imported listings as ordinary supplement inventory.2
FAQ
Is armodafinil a nootropic?
2It is a wakefulness promoting prescription drug. It may improve wakefulness in specific prescription-labeled sleepiness contexts, but it is not a dietary supplement or a validated healthy user memory/study stack ingredient.
Can it interfere with birth control?
2Yes. Labeling warns that steroidal contraceptives may be less effective during armodafinil use and for a period after stopping. This is a medical counseling issue, not a checkout page detail.
Who should avoid unsupervised use?
2People with heart disease, high blood pressure, arrhythmia history, psychiatric conditions, rash or hypersensitivity history with modafinil/armodafinil, pregnancy or breastfeeding, hormonal contraception reliance, stimulant stacking, or anti doping exposure should avoid unsupervised use.
References
- PubChem. Armodafinil, CID 9690109. Accessed 2026-06-30.
- DailyMed. Armodafinil tablet label, revised February 2024. Accessed 2026-08-21.
- Czeisler CA, Walsh JK, Wesnes KA, Arora S, et al. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study. Mayo Clinic Proceedings. 2009;84(11):958-972.
- Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives. Clinical Drug Investigation. 2009;29(9):613-623.
- Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. Journal of Clinical Sleep Medicine. 2010;6(5):458-466.
- Mello J, et al. Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. EClinicalMedicine. 2024;76:102843.
- World Anti-Doping Agency. The 2026 Prohibited List. Accessed 2026-06-30.